Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 14, 2016, Pages 3791-3796

  Zunke, Friederike ^a   Andresen, Lisa ^a   Wesseler, Sophia ^a   Groth, Johann ^a   Arnold, Philipp ^a   Rothaug, Michelle ^a   Mazzulli, Joseph R ^b   Krainc, Dimitri ^b   Blanz, Judith ^a   Saftig, Paul ^a   Schwake, Michael ^b,c  

^a UNIVERSITY OF KIEL   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BIELEFELD UNIVERSITY   (Germany)

Author keywords

Gaucher's disease; GC activators; LIMP 2; Parkinson's disease; glucocerebrosidase

Indexed keywords

ALPHA SYNUCLEIN; BETA GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN TYPE 2; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; PROTEIN BINDING;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; GAUCHER DISEASE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOFLUORESCENCE; LIGAND BINDING; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; COS CELL LINE; GENETICS; LYSOSOME; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; ANIMALS; BINDING SITES; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CRYSTALLOGRAPHY, X-RAY; GLUCOSYLCERAMIDASE; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; LYSOSOMES; MICE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84962727864     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1514005113     Document Type: Article

References (35)

1. Reczek D, et al. (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphateindependent targeting of beta-glucocerebrosidase. Cell 131(4):770-783.
2. Blanz J, et al. (2015) Mannose 6-phosphate-independent Lysosomal Sorting of LIMP-2. Traffic 16(10):1127-1136.
3. Blanz J, et al. (2010) Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. Hum Mol Genet 19(4):563-572.
4. Berkovic SF, et al. (2008) Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet 82(3):673-684.
5. Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29(5):567-583.
6. Nalls MA, et al. (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70(6):727-735.
7. Westbroek W, Gustafson AM, Sidransky E (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 17(9):485-493.
8. Gegg ME, et al. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72(3):455-463.
9. Rothaug M, et al. (2014) LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proc Natl Acad Sci USA 111(43):15573-15578.
10. Bras J, et al. (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 23(23):6139-6146.
11. Sardi SP, et al. (2011) CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 108(29):12101-12106.
12. Sardi SP, et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 110(9):3537-3542.
13. Siebert M, Sidransky E, Westbroek W (2014) Glucocerebrosidase is shaking up the synucleinopathies. Brain 137(Pt 5):1304-1322.
14. Mazzulli JR, et al. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146(1):37-52.
15. Neculai D, et al. (2013) Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 504(7478):172-176.
16. Brumshtein B, Wormald MR, Silman I, Futerman AH, Sussman JL (2006) Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr D Biol Crystallogr 62(Pt 12):1458-1465.
17. Dvir H, et al. (2003) X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 4(7):704-709.
18. Cormand B, et al. (1998) Mutation analysis of Gaucher disease patients from Argentina: High prevalence of the RecNciI mutation. Am J Med Genet 80(4):343-351.
19. Kawame H, Eto Y (1991) A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients. Am J Hum Genet 49(6):1378-1380.
20. Zhao Y, Ren J, Padilla-Parra S, Fry EE, Stuart DI (2014) Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor. Nat Commun 5:4321.
21. Düsterhöft S, et al. (2015) Extracellular juxtamembrane segment of ADAM17 interacts with membranes and is essential for its shedding activity. Biochemistry 54(38):5791-5801.
22. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55(6):1189-1193.
23. Horst M, Knecht EC, Schu PV (1999) Import into and degradation of cytosolic proteins by isolated yeast vacuoles. Mol Biol Cell 10(9):2879-2889.
24. Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D (2016) Alpha-synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci USA 113(7):1931-1936.
25. Liou B, et al. (2006) Analyses of variant acid beta-glucosidases: Effects of Gaucher disease mutations. J Biol Chem 281(7):4242-4253.
26. Grace ME, Graves PN, Smith FI, Grabowski GA (1990) Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations. J Biol Chem 265(12):6827-6835.
27. Atrian S, et al. (2008) An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease. Proteins 70(3):882-891.
28. Lieberman RL (2011) A guided tour of the structural biology of Gaucher disease: Acid-β-glucosidase and saposin C. Enzyme Res 2011:973231.
29. Sly WS, Kaplan A, Achord DT, Brot FE, Bell CE (1978) Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 23:547-551.
30. Stahl PD, Rodman JS, Miller MJ, Schlesinger PH (1978) Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA 75(3):1399-1403.
31. Pastores GM, et al. (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4, Suppl 5):4-14.
32. Liou B, Haffey WD, Greis KD, Grabowski GA (2014) The LIMP-2/SCARB2 binding motif on acid β-glucosidase: Basic and applied implications for Gaucher disease and associated neurodegenerative diseases. J Biol Chem 289(43):30063-30074.
33. Benito JM, García Fernández JM, Ortiz Mellet C (2011) Pharmacological chaperone therapy for Gaucher disease: A patent review. Expert Opin Ther Pat 21(6):885-903.
34. Patnaik S, et al. (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem 55(12):5734-5748.
35. Pearson K (1909) Determination of the Coefficient of Correlation. Science 30(757): 23-25.